Belite Bio (BLTE) Return on Capital Employed (2023 - 2025)
Belite Bio (BLTE) posted quarterly Return on Capital Employed of 2978301.27% for Q4 2025, down 294703644.0% year-over-year from N/an in Q4 2024, and up 59.51% quarter-over-quarter from 7356153.3% in Q3 2025.
Belite Bio (BLTE) Return on Capital Employed (2023 - 2025) Analysis & Trends
Belite Bio's Return on Capital Employed history runs 3 years deep, the most recent figure standing at 2978301.27% for Q4 2025.
- In Q4 2025, Return on Capital Employed fell 294703644.0% year-over-year to 2978301.27%; the TTM figure through Dec 2025 stood at 2978301.27% (down 294703644.0% YoY), while the FY2025 annual figure was 18.45%, up 1564.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 2978301.27%, up from 7356153.3% in the prior quarter.
- The five-year high for Return on Capital Employed was 31264.83% in Q4 2024, with the low at 9613810.7% in Q4 2023.
- The 3-year median for Return on Capital Employed is 5167227.29% (2025), against an average of 4994882.52%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed surged 958254587 bps in 2024, then tumbled 294703644 bps in 2025.
- Belite Bio's Return on Capital Employed stood at 9613810.7% in 2023, then surged by 100 bps to 31264.83% in 2024, then sank by 9426 bps to 2978301.27% in 2025.
- Business Quant data shows BLTE's Return on Capital Employed at 2978301.27% in Q4 2025, 7356153.3% in Q3 2025, and 31264.83% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,978,301.27% |
| Sep 30, 2025 | -7,356,153.30% |
| Dec 31, 2024 | -31,264.83% |
| Dec 31, 2023 | -9,613,810.70% |